Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for YungShin Global Holding Co's Debt-to-EBITDA or its related term are showing as below:
TPE:3705'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.63 Med: 2 Max: 2.8
Current: 0.85
During the past 13 years, the highest Debt-to-EBITDA Ratio of YungShin Global Holding Co was 2.80. The lowest was 0.63. And the median was 2.00.
TPE:3705's Debt-to-EBITDA is ranked better than 64.46% of 681
companies
in the Drug Manufacturers industry
Industry Median: 1.63
vs TPE:3705: 0.85
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
YungShin Global Holding Co Debt-to-EBITDA Related Terms
YungShin Global Holding Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, YungShin Global Holding Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
YungShin Global Holding Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, YungShin Global Holding Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where YungShin Global Holding Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
YungShin Global Holding Co (TPE:3705) has a Debt-to-EBITDA of 0.89 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on YungShin Global Holding Co. This is 56% below median its historical median of 2.00. Over the past decade, YungShin Global Holding Co's Debt-to-EBITDA has ranged from 0.63 to 2.80. According to the industry distribution chart, YungShin Global Holding Co ranks #242 out of 681 companies in the Drug Manufacturers industry, placing it in the top 35.5%.
Is YungShin Global Holding Co's Debt-to-EBITDA too high?
YungShin Global Holding Co's current Debt-to-EBITDA of 0.89 is 56% below median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 0.63 to a high of 2.80. The Drug Manufacturers industry median Debt-to-EBITDA is 1.63. YungShin Global Holding Co's value of 0.89 is 45.4% below this industry median. Based on the distribution chart, YungShin Global Holding Co ranks #242 out of 681 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, YungShin Global Holding Co has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does YungShin Global Holding Co's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, YungShin Global Holding Co ranks #242 out of 681 companies for Debt-to-EBITDA. This puts YungShin Global Holding Co in the upper half of its industry. The industry median Debt-to-EBITDA is 1.63. YungShin Global Holding Co's value of 0.89 is 45.4% below this benchmark. Historically, YungShin Global Holding Co's own Debt-to-EBITDA has ranged from 0.63 to 2.80 over the past decade. While the company's 10-year median is 2.00 vs. the industry median of 1.63, YungShin Global Holding Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.63, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. YungShin Global Holding Co's current Debt-to-EBITDA of 0.89 is 45.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on YungShin Global Holding Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. YungShin Global Holding Co's current Debt-to-EBITDA is 0.89, which is 56% below median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is YungShin Global Holding Co stock overvalued right now?
Based on GuruFocus' analysis, YungShin Global Holding Co (TPE:3705) is currently considered Fairly Valued. The stock's GF Value™ is NT$55.52, compared to a current price of NT$54.40 — trading 2% below its estimated fair value. The current Debt-to-EBITDA is 0.89, which is 56% below median its 10-year median of 2.00 and 45.4% below the Drug Manufacturers industry median of 1.63. YungShin Global Holding Co's overall GF Score™ is 89/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For YungShin Global Holding Co (TPE:3705), the current Debt-to-EBITDA is 0.89 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is YungShin Global Holding Co (TPE:3705) Overvalued in 2026?
Based on GuruFocus' analysis, YungShin Global Holding Co stock appears to be undervalued.
The current stock price of NT$54.40 is trading 2% below its estimated GF Value™ of NT$55.52.
GuruFocus considers YungShin Global Holding Co to be Fairly Valued.
Key valuation signals for TPE:3705:
Debt-to-EBITDA: 0.89 (56% below median its 10-year median of 2.00)
GF Value™: NT$55.52 vs. price of NT$54.40 (2% below fair value)
Industry Position: 45.4% below the Drug Manufacturers median (#242 of 681)
No single metric tells the full story. See the TPE:3705 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
YungShin Global Holding Co Ltd invests, manufactures, and sells medicines, animal drugs, agricultural chemicals, industrial medicine, and cosmetics. The company derives revenue from the sale of Human drugs, Health food, Animal drugs, and Others. The company generates the majority of its revenue from Human drugs. Geographically, the company generates the revenue from Taiwan, the USA, Japan, and China, out of which the majority of its revenue is generated from Taiwan.
89GF Score
Get the complete analysis for TPE:3705
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:3705 has been successfully added to your 
